arrow
R

Rhine R. Shen

kite a gilead company
H指数:23
被引数:3,177

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic correlates of clinical CAR T cell activity

临床CAR T细胞活性的基因组相关性

2026-07-240
PRE
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

ZUMA-2接受anti-CD19 car-t细胞治疗的复发/难治性套细胞淋巴瘤患者的五年随访,队列1和2

2026-04-270
OAAI
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Brexucabtagene autoleucel 用于 BTKi 初治的复发/难治性套细胞淋巴瘤:ZUMA-2 研究队列 3 的主要分析

Blood
IF23.1
2025-10-310
PRE
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)

与CD19-directed CAR T细胞疗法 (axicabtagene ciloleucel) 治疗的大b细胞淋巴瘤的预后相关的肿瘤基因表达特征

2025-02-270
OAAI
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Treated with Ciloleucel

炎症、肿瘤和产品属性对接受Ciloleucel治疗的复发/难治性滤泡性淋巴瘤患者临床结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

ZUMA-2研究队列1和2中接受Brexucabtagene autoleucel(Brexu-cel)治疗的复发/难治性套细胞淋巴瘤(R/R MCL)患者的五年结局

BLOOD
IF23.1
2024-11-050
PRE
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

肿瘤微环境对大b细胞淋巴瘤anti-CD19 CAR T细胞治疗或化疗及移植疗效的影响

2024-01-1721
OAAI
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
2023-11-179
OAAI
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
2014-04-03186
OA